Oncology
Revealing the molecular mechanism of tumor development and identifying the matching inhibitory candidates is one important area within the cancer research.
The tumor diversity is extremely high. Therefore, cancer research belongs to the high variant research areas with manifold scientific approaches.
To match this challenge, we offer you a unique diversity of products for your oncology research and development in the academic and pharmaceutical field.
Click on the organs and learn more about cancer types
General information
Oncologists focus on the diagnosis, therapy and follow-up of cancer.
Cancer is a class of diseases in which cells start to divide uncontrollably and invade other tissues. Cancer cells can spread to other parts of the body via the blood and lymphatic system. Under physiological conditions, cell proliferation is tightly controlled by many mechanisms. In addition, the immune system is able to recognize and destroy cancer cells. If these mechanisms fail or the immune system cannot effectively destroy the cells, it can lead to a malignant tumor. Theoretically, a malignant neoplasm can occur everywhere, but there are cancers that are more often than others. For men it is the prostate and in women it is the mammary gland.
Relevant products for oncology research
| Name | Price | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| p75 NGF Receptor Blocking Peptide | Login | p75 NGF Receptor Blocking Peptide | ||||||||||||||||
|
||||||||||||||||||
| TrkA Blocking Peptide | Login | TrkA Blocking Peptide | ||||||||||||||||
|
||||||||||||||||||
| TrkB Blocking Peptide | Login | TrkB Blocking Peptide | ||||||||||||||||
|
||||||||||||||||||
| TrkC Blocking Peptide | Login | TrkC Blocking Peptide | ||||||||||||||||
|
||||||||||||||||||
| Ret Blocking Peptide | Login | Ret Blocking Peptide | ||||||||||||||||
|
||||||||||||||||||
| Human Tumor Necrosis Factor Rec 2 (ext) Blocking Peptide | Login | Human Tumor Necrosis Factor Rec 2 (ext) Blocking Peptide | ||||||||||||||||
|
||||||||||||||||||
| IGF1R Blocking Peptide | Login | IGF1R Blocking Peptide | ||||||||||||||||
|
||||||||||||||||||
| ENT1/SLC29A1 Blocking Peptide | Login | ENT1/SLC29A1 Blocking Peptide | ||||||||||||||||
|
||||||||||||||||||
| CD73 Blocking Peptide | Login | CD73 Blocking Peptide | ||||||||||||||||
|
||||||||||||||||||
| NKCC1/SLC12A2 Blocking Peptide | Login | NKCC1/SLC12A2 Blocking Peptide | ||||||||||||||||
|
||||||||||||||||||
| xCT/SLC7A11 Blocking Peptide | Login | xCT/SLC7A11 Blocking Peptide | ||||||||||||||||
|
||||||||||||||||||
| Kv3.1b/KCNC1 Blocking Peptide | Login | Kv3.1b/KCNC1 Blocking Peptide | ||||||||||||||||
|
||||||||||||||||||
| KCNH2/erg1 Blocking Peptide | Login | KCNH2/erg1 Blocking Peptide | ||||||||||||||||
|
||||||||||||||||||
| KCNH2/HERG Blocking Peptide | Login | KCNH2/HERG Blocking Peptide | ||||||||||||||||
|
||||||||||||||||||
| KCNH2/HERG Blocking Peptide | Login | KCNH2/HERG Blocking Peptide | ||||||||||||||||
|
||||||||||||||||||
| Chelerythrine | Login | Chelerythrine | ||||||||||||||||
|
||||||||||||||||||
| Chelerythrine | Login | Chelerythrine | ||||||||||||||||
|
||||||||||||||||||
| Chelerythrine | Login | Chelerythrine | ||||||||||||||||
|
||||||||||||||||||
| Semaphorin 4D/SEMA4D Blocking Peptide | Login | Semaphorin 4D/SEMA4D Blocking Peptide | ||||||||||||||||
|
||||||||||||||||||
| Slitrk2 Blocking Peptide | Login | Slitrk2 Blocking Peptide | ||||||||||||||||
|
||||||||||||||||||
| TSH Receptor/TSHR Blocking Peptide | Login | TSH Receptor/TSHR Blocking Peptide | ||||||||||||||||
|
||||||||||||||||||
| MERTK (extracellular) Blocking Peptide | Login | MERTK (extracellular) Blocking Peptide | ||||||||||||||||
|
||||||||||||||||||
| Human ZACN Blocking Peptide | Login | Human ZACN Blocking Peptide | ||||||||||||||||
|
||||||||||||||||||
| ZIP3/SLC39A3 Blocking Peptide | Login | ZIP3/SLC39A3 Blocking Peptide | ||||||||||||||||
|
||||||||||||||||||
| AXL (extracellular) Blocking Peptide | Login | AXL (extracellular) Blocking Peptide | ||||||||||||||||
|
||||||||||||||||||


